Sanofi's Shantha prepared to deliver 37M doses of long-delayed pediatric vaccine

Sanofi ($SNY) faced a long delay before its Indian affiliate, Shantha Biotechnics, finally came through with the launch of its low-cost pediatric pentavalent vaccine, Shan5. But now that it has, it says it's ready to deliver 37 million doses of the jab--and it's already begun, handing over 400,000 to aid immunization in Gwalior and Jabalpur. More from FierceVaccines

Suggested Articles

Three facts about how distributors are managing in-demand inventory.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.

Purdue has reached an $8 billion settlement with the U.S. government to settle criminal and civil charges for its role in the U.S. opioid crisis.